Accelerate to discover

Back to filter

Related topics

Identify the quality of any protein in 3 minutes using microliters of sample with Tycho

NanoTemper

Jul 19, 2019

Tycho tells you so much about the quality of your protein. It tells you about presence, purity, concentration,...

Expanding patient tumor samples has never been so easy - Discover AVATAR

Xcell Biosciences

Jul 10, 2019

The AVATAR Cell Control System lets you fine-tune oxygen and pressure to cater culture conditions to your cell type of...

Take advantage of 4D mode

VisualSonics FujiFilm

Jul 4, 2019

Cutting edgce cardiovascular research demands cutting edge technology. 4D imaging brings together dynamic motion and 3D...

CQ1 confocal quantitative image cytometer: fighting colon cancer with killer cells

Yokogawa

Jul 2, 2019

Genetically modified immune cells can successfully destroy colon cancer cells. This has been demonstrated for the first...

Jul 21, 2019

Assessment of angiotensin II-induced mouse models of abdominal aortic aneurysm

VisualSonics FujiFilm

Jun 28, 2019

Are you working with high ultrasound imaging and are you interesting in progression/ regression of abdominal aortic...

Bionano introduce new SP blood and cell culture DNA isolation kit

BioNano Genomics

Jun 26, 2019

This Bionano prep SP blood and cell culture DNA isolation kit, can provide ultra-high molecular weight (UHMW) gDNA in...

Breast cancer‐derived exosomes reflect the cell of origin phenotype

IZON

Jun 24, 2019

The qNano Gold measures particles using the Tunable Resistive Pulse Sensing (TRPS) principle. TRPS is the most powerful...

Jul 21, 2019

Transcutaneous implantation of valproic acid-encapsulated

Spectral Instruments Imaging

Jun 21, 2019

The interest in alternative material systems and delivery methods for treatment of androgenetic alopecia has been...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey